L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial.

CONTEXT The amino acid L-arginine is a substrate for nitric oxide synthase and is increasingly used as a health supplement. Prior studies suggest that L-arginine has the potential to reduce vascular stiffness. OBJECTIVE To determine whether the addition of L-arginine to standard postinfarction therapy reduces vascular stiffness and improves ejection fraction over 6-month follow-up in patients following acute ST-segment elevation myocardial infarction. DESIGN AND SETTING Single-center, randomized, double-blind, placebo-controlled trial with enrollment from February 2002 to June 2004. PATIENTS A total of 153 patients following a first ST-segment elevation myocardial infarction were enrolled; 77 patients were 60 years or older. INTERVENTION Patients were randomly assigned to receive L-arginine (goal dose of 3 g 3 times a day) or matching placebo for 6 months. MAIN OUTCOME MEASURES Change in gated blood pool-derived ejection fraction over 6 months in patients 60 years or older randomized to receive L-arginine compared with those assigned to receive placebo. Secondary outcomes included change in ejection fraction in all patients enrolled, change in noninvasive measures of vascular stiffness, and clinical events. RESULTS Baseline characteristics, vascular stiffness measurements, and left ventricular function were similar between participants randomized to receive placebo or L-arginine. The mean (SD) age was 60 (13.6) years; of the participants, 104 (68%) were men. There was no significant change from baseline to 6 months in the vascular stiffness measurements or left ventricular ejection fraction in either of the 2 groups, including those 60 years or older and the entire study group. However, 6 participants (8.6%) in the L-arginine group died during the 6-month study period vs none in the placebo group (P = .01). Because of the safety concerns, the data and safety monitoring committee closed enrollment. CONCLUSIONS L-arginine, when added to standard postinfarction therapies, does not improve vascular stiffness measurements or ejection fraction and may be associated with higher postinfarction mortality. L-arginine should not be recommended following acute myocardial infarction. Clinical Trial Registration ClinicalTrials.gov, NCT00051376.

[1]  E. Lakatta,et al.  Elevated Aortic Pulse Wave Velocity, a Marker of Arterial Stiffness, Predicts Cardiovascular Events in Well-Functioning Older Adults , 2005, Circulation.

[2]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[3]  R. Böger,et al.  L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. , 2005, Alternative medicine review : a journal of clinical therapeutic.

[4]  D. Reed-Gillette,et al.  Prevalence of leading types of dietary supplements used in the Third National Health and Nutrition Examination Survey, 1988--94. , 2004, Advance data.

[5]  D. Kass,et al.  Age and gender affect ventricular-vascular coupling during aerobic exercise. , 2004, Journal of the American College of Cardiology.

[6]  R. Jacob,et al.  Effects of HMG-CoA Reductase Inhibitors on Endothelial Function: Role of Microdomains and Oxidative Stress , 2004, Circulation.

[7]  A. Shoukas,et al.  Arginase Reciprocally Regulates Nitric Oxide Synthase Activity and Contributes to Endothelial Dysfunction in Aging Blood Vessels , 2003, Circulation.

[8]  J. Hochman,et al.  Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. , 2003, Circulation.

[9]  R. Ferrante,et al.  Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Daniel Levy,et al.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. , 2003, Circulation.

[11]  Daniel Levy,et al.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. , 2003, Circulation.

[12]  J. Astern,et al.  Effects of Chronic Treatment With l-Arginine on Atherosclerosis in ApoE Knockout and ApoE/Inducible NO Synthase Double-Knockout Mice , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[13]  V. Berger Improving the information content of categorical clinical trial endpoints. , 2002, Controlled clinical trials.

[14]  David J. Webb,et al.  Nitric Oxide Regulates Local Arterial Distensibility In Vivo , 2002, Circulation.

[15]  R. Cannon Oral L-arginine (and other active ingredients) for ischemic heart disease?. , 2002, Journal of the American College of Cardiology.

[16]  Judy W. M. Cheng,et al.  L-Arginine in the Management of Cardiovascular Diseases , 2001, The Annals of pharmacotherapy.

[17]  R. Cannon,et al.  Oral L-arginine in patients with coronary artery disease on medical management. , 2000, Circulation.

[18]  J. Loscalzo What we know and don't know about L-arginine and NO. , 2000, Circulation.

[19]  J. Lachin Worst-rank score analysis with informatively missing observations in clinical trials. , 1999, Controlled clinical trials.

[20]  P. Tsao,et al.  Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. , 1998, Circulation.

[21]  B. Fetics,et al.  Estimation of Central Aortic Pressure Waveform by Mathematical Transformation of Radial Tonometry Pressure Data , 1998 .

[22]  S. Higano,et al.  Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. , 1998, Circulation.

[23]  L A Moyé,et al.  Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. , 1997, Circulation.

[24]  J. Cooke,et al.  Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. , 1997, Circulation.

[25]  D. Levy,et al.  Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. , 1997, Circulation.

[26]  C. H. Chen,et al.  Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. , 1997, Circulation.

[27]  D. Celermajer,et al.  Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. , 1997, Atherosclerosis.

[28]  M. Petch,et al.  Aging-associated endothelial dysfunction in humans is reversed by L-arginine. , 1996, Journal of the American College of Cardiology.

[29]  K. Lee,et al.  Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. , 1996, Circulation.

[30]  T. Rector,et al.  Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. , 1996, Circulation.

[31]  A. Keech,et al.  Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. , 1996, The Journal of clinical investigation.

[32]  G. B. John Mancini,et al.  Angiotensin Converting Enzyme Inhibition, with Quinapril, Improves Endothelial Vasomotor Dysfunction in Patients with Coronary Artery Disease: the TREND Study (Trial on REversing ENdothelial Dysfunction) , 1996 .

[33]  T. Lüscher,et al.  Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. , 1996, Circulation.

[34]  R. Wilson,et al.  Direct effects of smooth muscle relaxation and contraction on in vivo human brachial artery elastic properties. , 1995, Circulation research.

[35]  E. McVeigh,et al.  Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarction. , 1995, The American journal of cardiology.

[36]  L. Ghiadoni,et al.  Aging and endothelial function in normotensive subjects and patients with essential hypertension. , 1995, Circulation.

[37]  D. Spiegelhalter,et al.  Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. , 1994, Journal of the American College of Cardiology.

[38]  J. F. Burke,et al.  The plasma flux and oxidation rate of ornithine adaptively decline with restricted arginine intake. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  B. Chaitman,et al.  Impact of Age on Clinical Outcome and Postlytic Management Strategies in Patients Treated With Intravenous Thrombolytic Therapy: Results From the TIMI II Study , 1994, Circulation.

[40]  F. Harrell,et al.  Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. , 1994, Circulation.

[41]  G. Lamas,et al.  Quantitative Two-Dimensional Echocardiographic Measurements are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction: The Protective Effect of Captopril , 1994, Circulation.

[42]  M. Yokota,et al.  Relation between ventriculoarterial coupling and myocardial energetics in patients with idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.

[43]  A. Maseri,et al.  Age-Related Increase in Mortality among Patients with First Myocardial Infarctions Treated with Thrombolysis , 1993 .

[44]  David A. Kass,et al.  Effective Arterial Elastance as Index of Arterial Vascular Load in Humans , 1992, Circulation.

[45]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[46]  S. Moncada,et al.  EFFECTS OF ENDOTHELIUM-DERIVED NITRIC OXIDE ON PERIPHERAL ARTERIOLAR TONE IN MAN , 1989, The Lancet.

[47]  S Sasayama,et al.  Ventriculoarterial coupling in normal and failing heart in humans. , 1989, Circulation research.

[48]  F. Yin,et al.  Aortic Compliance in Human Hypertension , 1989, Hypertension.

[49]  P. Ganz,et al.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. , 1986, The New England journal of medicine.

[50]  A P Avolio,et al.  Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. , 1985, Circulation.

[51]  JosephLoscalzo Adverse Effects of Supplemental l-Arginine in Atherosclerosis , 2003 .

[52]  D. Kereiakes,et al.  Endothelial dysfunction. , 2003, Circulation.

[53]  S. Bode-Böger,et al.  The clinical pharmacology of L-arginine. , 2001, Annual review of pharmacology and toxicology.

[54]  H. Drexler,et al.  Endothelial dysfunction: clinical implications. , 1997, Progress in cardiovascular diseases.

[55]  P. López-Jaramillo,et al.  The L-arginine: nitric oxide pathway. , 1993, Current opinion in nephrology and hypertension.

[56]  S. Morris,et al.  Regulation of enzymes of urea and arginine synthesis. , 1992, Annual review of nutrition.